Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 11/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25755571 | 0.92 | DRD2 (0.48) | CACNA1HDRD2EPHX1SIGMAR1TDP1 | |
| SCHEMBL24068421 | 0.90 | CACNA1H (0.39) | CACNA1HDRD2JAK2JAK1EPHX1 | |
| SCHEMBL25755480 | 0.89 | DRD2 (0.40) | CACNA1HDRD2JAK2JAK1EPHX1 | |
| SCHEMBL25755605 | 0.89 | DRD2 (0.42) | CACNA1HDRD2EPHX1SIGMAR1TDP1 | |
| SCHEMBL16480069 | 0.80 | CACNA1H (0.54) | CACNA1HDRD2JAK2JAK1EPHX1 | |
| SCHEMBL31301242 | 0.79 | DRD2 (0.63) | CACNA1HDRD2EPHX1SIGMAR1CD274 | |
| SCHEMBL14614740 | 0.79 | CACNA1H (0.53) | CACNA1HDRD2JAK2JAK1EPHX1 | |
| SCHEMBL24951961 | 0.78 | DRD2 (0.53) | CACNA1HDRD2JAK2JAK1EPHX1 | |
| SCHEMBL24811481 | 0.78 | CACNA1H (0.52) | CACNA1HDRD2JAK2JAK1EPHX1 | |
| SCHEMBL14708214 | 0.78 | CACNA1H (0.52) | CACNA1HDRD2JAK2JAK1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3865152-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | CACNA1H 4326/4885DRD2 4439/4885JAK2 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.